#37 – Winter Is Coming: Update on Flu, COVID and RSV
Show notes
With the respiratory virus season starting, Florian Krammer gives an overview of what’s circulating and how to protect yourself. He explains why respiratory viruses spread more easily in the cold and how influenza plays ping pong between the northern and southern hemispheres. The focus is on the three viruses we have good countermeasures for. For SARS-CoV-2, the share of severe infections has been falling steadily since 2022, last year’s vaccines reached an effectiveness of 50 to 60 percent, and new options like the Spanish protein vaccine Bimervax and a combined COVID and flu mRNA vaccine are now available in Europe. Influenza causes 3 to 5 million severe cases and up to 650,000 deaths worldwide every year. An early H1N1 rise closely matches this year’s vaccine strain, and an mRNA flu vaccine has now been licensed in the US. For RSV, there are vaccines for adults over 60, maternal vaccination to protect newborns, and a monoclonal antibody for babies. Plus: why N95 masks and antivirals like Paxlovid, taken early, are useful additions.
SARS-CoV-2 variant data from the US CDC: https://www.cdc.gov/covid/php/variants/variants-and-genomic-surveillance.html
Influenza surveillance data from the US CDC: https://www.cdc.gov/fluview/
+++++
You can support the podcast via our German Steady page: https://steady.page/virologisch/
Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com
+++++
Krammer laboratory information
Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/
Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/
+++++
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.
I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).
My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.
My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.
My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
Show transcript
00:00:05: One interesting thing to mention with SARS-CoV-II is also that in many cases, at least in the northern hemisphere we now often see a weird double season.
00:00:14: There's this first big coming end of August and then there was a winter wave after it.
00:00:33: Virological – With Florian Kramer.
00:00:46: Hello!
00:00:47: And welcome to todays weeks episode of ViroLogical.
00:00:50: This was recorded on October twentieth of twenty-twenty six in New York.
00:00:57: Yeah, it's already end of October and I thought i would do an update about seasonal respiratory viruses because yeah the season is starting and I think its good to get an idea but what out there?
00:01:13: how you can protect yourself?
00:01:16: And so today we are going talk these seasonal respiratory virus that or sometimes just a pain not very nasty, and sometimes unfortunately can cause serious infections including infections that lead to hospitalizations.
00:01:32: First of all the question is why do we see an increase in these infections during the colder season?
00:01:41: Right now it's getting winter at a northern hemisphere... ...and we also see an increasing this infection in winter in southern Hemisphere.
00:01:49: so there's a seasonality to it!
00:01:51: That's what I call them seasonal respiratory viruses and for example seasonal influenza, right?
00:01:59: And there might be a number of reasons.
00:02:01: First off all it seems that when the temperatures are lower these viruses are more stable also if the temperature is lower.
00:02:10: people spend time inside and this leads to more contact where not much ear exchange could lead an increase in infections.
00:02:23: The humidity might also play a role in this case.
00:02:28: The microbiome, in our respiratory tract may change over the seasons and that would make us more susceptible to infection.
00:02:36: so it could be a number of reasons why this is the case.
00:02:40: There are seasonal or there are infections with seasonal respiratory viruses in the tropics and subtropics year-round.
00:02:49: So its not like.
00:02:50: These viruses cannot infect people if it's not cold, but seems that the drop of temperature and getting into winter season enhances their transmission.
00:03:03: What is also interesting to think about this... We have an increase in activity on these viruses in the northern hemisphere in winter.
00:03:18: It seems what some of these viruses do is they play ping-pong between the hemispheres.
00:03:23: So basically through travel, They move from The southern hemisphere when it's Basically getting warmer there in In the southern Hemisphere spring to the north northern Hemisphere When its getting colder There and then it gets winter And then they spread there.
00:03:40: Then this goes back To the south when Its Winter.
00:03:44: Not all Of them necessarily Do that but Some like influenza.
00:03:48: All right, there's actually a lot of viruses that cause these seasonal infections.
00:03:55: We have influenza viruses, influenza A, influenza B but also influenza C. Influenza C is usually milder infection, influenza E and B can be pretty severe.
00:04:07: Of course SARS-CoV-II will talk about the seasonality of that virus in a few minutes.
00:04:13: we have seasonal coronaviruses.
00:04:15: they're related to SARS-Cov-II But they've been circulating in humans for quite some time.
00:04:20: They have funny names.
00:04:22: One of them is OC-VIII, another one is HKU-I.
00:04:27: The third one has two to nine E and the fourth one is NL-VI-III.
00:04:32: Those are just abbreviations for isolates from when they were first discovered.
00:04:38: But those viruses circulate in humans too there more causing common colds than severe infections.
00:04:44: but especially OC-IV can cause severe infections specifically in people who have pre-existing conditions.
00:04:53: Then we have a number of basically barymyxoviruses, respiratory syncytial virus or RSV.
00:05:00: for example is seasonal respiratory virus human metonymavirus, baryinfluenza virus one, beryinfluenzovirus two, Baryinffluenza virus three, Beryinfluence virus four.
00:05:14: then you have the rhinoviruses.
00:05:16: there's lot different types.
00:05:19: They can cause seasonal respiratory infections.
00:05:22: Enteroviruses are related to rhinoviruses, they're very similar... ...they can cause respiratory infections too despite their names which basically would suggest infections of the GI tract.. ..they can do that too but it can infect respiratory tract as well.
00:05:39: We have a lot different types of adenoviruses that could cause respiratory infection and then Boccovirus is another virus that can do this, there are many more.
00:05:50: And in addition to that we also have bacterial pathogens but I'm not going to talk about them because i am NOT a bacteriologist!
00:05:59: Let's start with the seasonal updates with SARS-CoV-II.
00:06:03: We all know SARS-Cov-II circulates since late two thousand nineteen beginning of twenty-twenty In humans has caused the covid-nineteen pandemic that has officially led to about seven million deaths.
00:06:18: If you look back and start to do predictions or estimates based on excess mortality, it's closer to thirty million deaths actually... It is quite a big number!
00:06:31: But what happened?
00:06:33: Basically starting in twenty-twenty two the deaths and infections started to decouple Initially, whenever you had a strong increase in infections or death and then over time the proportion of people dying from SARS-CoV-II went down.
00:06:52: Which is great!
00:06:53: And it's still sinking.
00:06:56: Don't get me wrong, SARS-COV-I-II infections can be highly problematic.
00:07:00: they can kill people.
00:07:01: unfortunately They could lead to long lasting problems.
00:07:09: these virus infections became in a way more and more inconsequential over time.
00:07:15: That doesn't mean you shouldn't get vaccinated, actually I think we should get vaccinated.
00:07:19: but the situation has improved a lot And this has a lot to do with baseline immunity In people.
00:07:24: People have a lot of immunities against SARS-CoV-II too now Antibodies, T cells Neutralizing antibodies, binding antibodies all kinds things.
00:07:33: So that helps the proportion of severe infections down.
00:07:41: And I hope this continues.
00:07:42: like that, maybe at some point SARS-CoV-II will behave like the human coronaviruses.
00:07:49: but as i said right now it's still good to get vaccinated against SARS-Cov-II too.
00:07:56: if you remember last year we had an update on the vaccine strain.
00:07:59: so they're updating the spike protein in the vaccine every year and last years vaccine was based.
00:08:11: that was a pretty good vaccine actually.
00:08:13: The vaccine effectiveness is always measured retrospectively, which means how well the vaccine worked in the population once it was rolled out.
00:08:21: and there's a number of papers out there that looked at effect on this last year's vaccines.
00:08:28: And if you look at those your effectiveness somewhere between fifty to sixty percent.
00:08:34: It's important.
00:08:35: keep in mind Of course, these numbers are not the ninety or ninety-five percent that we had in the beginning when this vaccines of their original COVID-nineteen vaccines were evaluated.
00:08:45: But there they read out was efficacy and not effectiveness.
00:08:49: And that's not the same.
00:08:51: Efficacy is what you get When your measure something in a clinical trial against the placebo control In a population That it pretty much naive.
00:08:59: now This fifty or sixty percent Is on top off The immunity that We already have.
00:09:05: So it's an add-on in a way, and so fifty to sixty percent is actually pretty good.
00:09:09: And this both against outpatient visits of people who are sick enough go see an emergency room or doctor's office... ...and also against hospitalizations.
00:09:19: It looked pretty similar This year the vaccine was updated again As I said that now happening every year.
00:09:28: The vaccine contains spike from variant called XFG.
00:09:33: That's a variant still circulating In some countries in Europe, the LB.A.V.
00:09:40: vaccine from last year is still available and because there's a high diversity of variants co-circulating right now XFG but many places that not even majority anymore than SWII RWI.RV.RFIXFC BQ I.VI and then BAIII.
00:10:04: So there's a mix of variants, and the XFG vaccine might work pretty well.
00:10:10: But I think that older generation vaccines would also work well against these super variants that are circulating specifically because in any case it has little bit of mismatch with what is circulating but its about really enhancing antibody titers and enhancing their immunity.
00:10:31: The other point i want to raise.
00:10:34: these variants that circulate, there's still some data from the US.
00:10:38: There is also some data form Europe and China about what circulating but few of this isolates are actually sequenced which means we know less-and-less about the variants that are circulating.
00:10:54: so during you know specifically in twenty one or twenty two when those variants came up ,there was a tonne of sequencing.
00:11:05: thousands and thousands of sequences were generated.
00:11:08: And now that's not really what people do anymore, there is a lot of resources spent on that.
00:11:13: so it leaves us with blind spots in terms of circulation.
00:11:17: In general there isn't much interest any more into what kind of SARS-CoV-II variants are circulating.
00:11:24: even the working group that was tracking this.
00:11:30: This is called SARS-CoV-II assessment of viral evolution or SAFE, it's a group with lots of scientists who came together to discuss results and do experiments on how well we are in for example match the vaccine.
00:11:45: The group was dissolved in September.
00:11:47: so... That happens everywhere right?
00:11:50: There're fewer and fewer resources for tracking SARS-Cov-II which makes it harder vaccine selection and recognizing new variants that come up.
00:12:02: But anyways, we have no vaccines from many different companies.
00:12:06: Moderna of course Pfizer, Novavex.
00:12:10: if you're in Europe You might come across a vaccine That's called Bymervex From the Spanish company called Hibra in use quite a bit.
00:12:20: I'm not going to go into details about the Moderna and Pfizer standard vaccines, and the Novavex vaccine because people know about that but this bimer wax is actually interesting.
00:12:31: it's a fusion of two receptor binding domains of the spike so very focused on this receptor-binding domain focused on inducing neutralizing antibodies.
00:12:40: This is a vaccine that's made in cell culture.
00:12:43: It's every common and protein vaccine That comes with an adjuvant.
00:12:48: it has been shown to be pretty good in terms of inducing neutralizing antibodies, maybe a little bit better than the Pfizer vaccine and may be less good.
00:12:57: I just wanted to mention this because now available is number of countries in EU.
00:13:08: Another vaccine that got approved by FDA and European Medicines Agency EMA is new Moderna vaccine that's called Mnex spike, and at least it has been shown in clinical trials to be about ten percent better than the other licensed vaccines.
00:13:29: And this is also focused.
00:13:32: so typically the Moderna Pfizer mRNA vaccines were coding for a whole spike protein.
00:13:38: This vaccine only codes for the NTT and the RBD So the N-terminal domain of the spike and the receptor binding domain that I mentioned for the bimovax vaccine.
00:13:50: And those two domains are main uses of neutralizing antibodies, the RPT more so than the entity.
00:13:58: but this is also a very focused vaccine in terms of neutralising antibodies.
00:14:04: Then if you're in Europe there's another mRNA vaccine on the market.
00:14:08: it's convenient called Mcombriax which was made by Moderna And that actually combines SARS-CoV-II and influenza.
00:14:18: So it has basically four components, it has SARS-Cov-II spike... ...and then it has the H one, H three and influenza B. Influenza components will get to that in a second.
00:14:29: But thats also an interesting vaccine because its combination.
00:14:33: It might be more convenient just getting one vaccine instead of getting a SARS-COV-I vaccine AND an influenza vaccine.
00:14:40: One interesting thing to mention with SARS-cov-II is In many cases, at least in the northern hemisphere we now often see a weird double season.
00:14:51: There's this first big coming end of August beginning of September that usually is smaller increase and then goes down And there are winter waves after it.
00:15:05: This kind very weird but has happened more or less over few years and it's going to be interesting to see if this continues or the seasonality just becomes basically a winter peak.
00:15:21: without that late summer increase, we are now seeing some depth.
00:15:27: Yeah!
00:15:27: That is from SARS-CoV-II.
00:15:29: The other virus I wanted to mention is seasonal influenza which of course has huge burden in terms of seasonal infections.
00:15:38: And these influenza infections also go from relatively mild to very severe and can of course, in some cases cause death.
00:15:49: Just as a reminder for seasonal influenza.
00:15:51: we have two influenza R subtypes that circulate H one N-one and H three N-two.
00:15:58: The H stands for the hemagglutinin which is one of the spike proteins then for the neuraminidase it's second spike protein.
00:16:05: Influenza viruses has two spike proteins and H-one, N-one just means hemagglutinin one noraminidase one.
00:16:12: It's kind of the type.
00:16:14: And then we have also influenza B circulating.
00:16:17: Those three viruses cause seasonal influenza.
00:16:22: Globally there are about three to five million severe cases of seasonal influenza every year between two hundred ninety to six hundred fifty thousand deaths.
00:16:33: that is estimated at WHO and US CDC.
00:16:38: Just to explain a little bit where the seasonal influenza is coming from.
00:16:42: So for the influenza A viruses, these are basically viruses that at some point caused the pandemic.
00:16:50: each one N-one in two thousand nine and then H three into in nineteen sixty eight.
00:16:56: And they just stayed in the population like SARS could we do?
00:16:58: They started to mutate.
00:17:00: But unlike SARS-CoV-II, they didn't become milder over time in terms of their infections.
00:17:06: With SARS-Covid-II we see a trend towards less lower percentage of severe infections.
00:17:12: now with influenza you don't necessarily see that which is interesting.
00:17:17: but yeah H one N one and H three and two come from historic pandemics.
00:17:22: Influenza B seems to have been in humans for very long.
00:17:27: Influenza B doesn't have an animal reservoir, so it does not cause pandemics and probably has been in humans for a very long time.
00:17:36: I already mentioned that the seasonal influenza viruses play ping-pong between hemispheres.
00:17:41: So in winter of the southern hemisphere they circulate there And then during the winter of northern hemisphere They circulated into the northern hemisphere.
00:17:53: Basically they are transported by the hemisphere via travel.
00:17:59: Every year, vaccine formulation for influenza is determined.
00:18:02: The virus changes a lot similar to SARS-CoV-II.
00:18:05: so the vaccines need to be updated and these formulations are currently trivalent meaning they have an H₁N₁ component, an HIII and II component in an influenza B component And just if somebody's interested... ...the H₂N component.
00:18:21: this here has a strain that called A MISURI-ELEVEN twenty-twenty five So isolated in the US.
00:18:29: The H-III and II strain is A, Darwin, fourteen fifty four twenty twenty five so that's...that was isolated in Australia.
00:18:39: And then the B strain is B, Tokyo EIS.
00:18:42: thirteen minus hundred seventy five.
00:18:46: Twenty twenty five complicated name but isolated in Tokyo as the names says a number of different vaccines for influenza.
00:19:01: We have inactivated vaccines, there's standard dose inactivate vaccines that are used in the general population and then we have high-dose vaccines and adjuvanted vaccines And those special inactivative vaccines Are for older people who don't make as good immune responses As younger.
00:19:24: In addition to that, in some countries including the United States there is a recombinant hemagglutinin vaccine on the market.
00:19:31: It's called FluBlock and it's made similar to Novavax SARS-CoV-II vaccine which actually also pretty good vaccine.
00:19:40: Typically in effectiveness studies this one of better ones.
00:19:46: And then there are flu mist in US and flu ends Europe.
00:19:51: It's basically the same vaccine, just has different names for whatever reason.
00:19:55: And that is a denuated vaccine not given by an intramascular injection like the other influenza vaccines but it´s given as nasal spray and its preferentially used in kids in US and Europe only licensed to kids.
00:20:11: so you spread this into your nose and then the virus in the nose replicates can't work, a can't replicate at higher temperatures so it can go to the lung.
00:20:22: And you basically induce immunity in your nose and then you don't get sick because that's what we call cold adapted and in this case also attenuated.
00:20:35: so basically weakened genetically weakened.
00:20:39: yeah as I said its pretty good vaccine for home administration.
00:20:45: So parents can actually order this vaccine by mail-order and then it comes home, And the parent's can apply these vaccines themselves to their kids which is easy because its just a nasal spray!
00:20:56: It has the bonus that it uses some mucosal immunity of course also doesn't have to be injected Which is great for kids.
00:21:06: As far as SARS-CoV-II typically after the season studies are published.
00:21:13: effectiveness of the vaccine, and usually in last season wasn't an exception.
00:21:20: The vaccine-effectiveness of the inactivated vaccines that are injected is somewhere between thirty percent to sixty percent And... Last year there was a early study from the UK That also looked at this life attenuated vaccine fluence or flu mist ...and it worked super well for kids actually had a vaccine effectiveness of about seventy-five percent, which is super high.
00:21:45: So I think that nasal spray for kids is pretty nice.
00:21:50: The EMA, so the European Regulatory Agency also discussing this home administration but i don't think it's available in european countries yet But i think its removing a barrier to getting the vaccine.
00:22:09: Another important thing when we talk about influenza is that it looked like a few weeks ago, that they would have very early season in the number of countries.
00:22:18: In Asia and Europe but also in the US.
00:22:21: so there seemed to be an increase in H-one N one cases But at least in the U S It now seems like this is going down again which is super interesting because That's typically not what happens with influenza.
00:22:34: usually once the seasons starts it really takes off kind of a little wave that seems to go down again and probably coming back later in winter.
00:22:48: And these initial cases were, as I said caused by H-one N one... ...and it seems that a lot those cases are caused by variant called D dot three dot one dot one which is not so bad because the variant in the vaccine that's trained at I mentioned the Missouri strain is D is D dot Three dot One.
00:23:09: So it's basically very similar to what seems to be circulating, which is good because that's what you want.
00:23:16: A match between the circulating vaccine and... Which is good?
00:23:21: Because That's What You Want a Match Between The Circulating Virus And The Vaccine!
00:23:26: A few more updates maybe.
00:23:28: There Is Now Also An mRNA Vaccine Against Influencer Licensed In
00:23:32: U.S.,
00:23:33: That's Called M-Fusiva, That Includes Age includes H-one, H-three and B hemagglutinin but encoded as mRNA.
00:23:43: And in phase three studies this is a Moderna vaccine as well.
00:23:47: it was shown that this vaccine is about twenty to thirty percent better compared to regular influenza vaccines.
00:23:54: so yeah some advantage!
00:23:58: The interesting thing is Moderna did all of these studies data package and a dossier basically to the FDA for reviews because they wanted to get this vaccine licensed.
00:24:13: And then, the FTA just rejected that back edge and said there not going look at it which is weird Because earlier of course these things were discussed with the FDA.
00:24:24: They probably had lot input on their study design so forth.
00:24:28: So There was alot of unhappiness also in community about.
00:24:35: And then a few weeks later the FDA reversed their opinion and took in this data package, this dossier.
00:24:42: The vaccine is now licensed to get licensed in August.
00:24:45: so that's another vaccine at least in US on the market.
00:24:51: I mentioned earlier these M-COMB reacts.
00:24:53: So basically it has an additional COVID-IX spike component.
00:25:04: In the US, you basically have now an mRNA vaccine against influenza and in Europe.
00:25:11: You have basically the same very similar mRNA vaccine Against Influenza that has in addition to spike from SARS-CoV-II to so as a combination of vaccine which is nice.
00:25:23: So just more options to protect yourself against flu if you like mRNA vaccines That's probably.
00:25:30: these are probably very good options.
00:25:32: If On traditional vaccines, there's a lot of good options for influenza and for SARS-CoV-II out there now too.
00:25:41: Alright the last virus that I wanted to discuss is respiratory syncytial virus or RSV That's Bermixovirus Now classified as pneumovirus was discovered in nineteen fifty six.
00:25:56: It causes a lot issues with infants And also older individuals.
00:26:02: attempts to make a vaccine early on were unsuccessful.
00:26:06: It took a long time until people got the technology right and it's basically structural biologists and virologists who figured out how do this, but now we have really good options to protect from RSV And there are two strategies.
00:26:25: The first one is targeted towards older adults People with sixty plus.
00:26:32: They need protection and for them there are actually three vaccines available.
00:26:37: One is called RXV, the other one is called a briswo And then another one that's called MResvia.
00:26:45: The first two are recombinant protein vaccines That have one of the spike proteins of RSV, diffusion protein... ...and that is recominantly made and formulated in a vaccine.
00:26:58: The last one, MResvia basically is an mRNA vaccine also by Moderna that encodes for the F protein.
00:27:06: And so all three vaccines are geared towards older people and they actually work really well... ...and don't need to be given every year!
00:27:14: So it seems there's protection over several seasons People still trying figure out when a booster dose is necessary.
00:27:22: but right now looks like at least two or three seasons of protection are certainly possible, maybe longer.
00:27:29: The other group that needs protection is infants and here there two strategies.
00:27:34: the first one is to vaccinate pregnant women basically in a third trimester between pregnancy weeks.
00:27:42: thirty-two to thirty six if thats within season for RSV.
00:27:48: And then the idea high titers of neutralizing antibody against the virus.
00:28:00: The antibody that circulates in blood, it's called IgG can actually cross the placenta.
00:28:07: and then these babies get born with already circulating antibodies against RSV in their own blood right?
00:28:18: The antibodies they got from their mothers And these antibodies have a half-life of about thirty days, so they slowly decline.
00:28:25: But the give this kids good protection against RSV in their first few months of life.
00:28:32: So that's one strategy.
00:28:34: The other strategies and thats for kids or moms who haven't been vaccinated is to give them monoclonal antibody Basically also neutralizing antibody against RS V that is engineered to have a long half-life, so even longer than the natural antibody.
00:28:52: And this is given... it's called Bephortus and these antibodies are given to babies under eight months of age when they enter their first RSV season.
00:29:04: again.
00:29:05: This is for babies whose moms were not vaccinated against RSV And that is a really good strategy.
00:29:12: This also protects them during the first year when they're confronted with RSV, and after their first years there's we.
00:29:19: infections are not as dramatic as problematic anymore but during the First Year.
00:29:25: often RSV Infections in unprotected babies lead to hospitalization even to death.
00:29:32: either vaccinating the moms or giving this molecular antibodies these kids can be well protected.
00:29:39: So we have these three viruses SARS-CoV-II, influenza and RSV for which we have pretty good countermeasures.
00:29:46: Pretty good vaccines but there are other viruses out there that can cause severe disease as well.
00:29:52: human methanomavirus is one of them HMBV, Baryinfluenza virus III another one of those.
00:29:58: and for those vaccines in development a lot of them are combination with RSV and will see how long it takes to get into the market.
00:30:09: hopefully some of them make it relatively quickly.
00:30:13: So we talked about these three viruses, We talked about vaccines.
00:30:16: I also wanted to mention that there's other countermeasures that protect you from getting infected and get sick or from getting severely sick.
00:30:26: The first counter measure is of course masks.
00:30:29: Remember if everybody is sick around you might be a good idea to mask up with an N- ninety five when you use public transport.
00:30:40: When you go to school, for example even if you go through a hospital... If you spend time in public spaces that are enclosed and where there's a lot of people who produce a lot aerosol and droplets filled with viruses also in planes for example trains, public transport in general.
00:30:58: it is really good idea to wear mask when they're lots of people sick.
00:31:02: And then there's drugs antiviral drugs against some of these viruses SARS-CoV-II and influenza that work super well if they're given early enough.
00:31:13: Typically, the given ones people start to have symptoms and once people tested positive for a certain virus because it needs to be specific rate If you give a flu drug against SARS-COV- II It's not going to help but they have to be given quickly.
00:31:28: Typically these trucks only work when they're given between forty-eight and seventy two hours, so to three days after symptom onset.
00:31:35: But then it works really well!
00:31:38: And for influenza we have neuro mini-dase inhibitors like Osildamevir.
00:31:42: We also have inhibitors of the polymerase of influenza.
00:31:46: that truck is called Baloxovir... ...and for SARS-CoV-II we have for example Paxilovid which is a broad-dased inhibitor and also works super well.
00:31:56: Most people don't know that, but this would also hypothetically work against seasonal coronaviruses.
00:32:01: It's just not prescribed for seasonal coronoviruses But yeah backslip.
00:32:06: it is actually broadly acting against all kinds of Coronaviruse.
00:32:10: So to summarize This was our twenty-twenty six episode about seasonal respiratory viruses.
00:32:17: I hope i could give you a good overview of what circulating and About vaccines that are important to counteract these infections.
00:32:26: I highly recommend the influenza vaccine, i recently got vaccinated with the flu vaccine and i also recommend the SARS-CoV-II vaccine.
00:32:36: ,i'm going to get that as soon as i am back in austria because i want to test bimerwax vaccine.
00:32:42: .I had so far all kinds of SARS-COV- II vaccines.
00:32:45: like to test different ones trying to get one that didn't have BimerWax so far And so I highly recommend these vaccines.
00:32:56: and of course for groups that are at risk for RSV, the RSV vaccine is also highly recommended.
00:33:02: Keep in mind there other countermeasures too including masks... ...and anti-viral drugs.
00:33:08: So fingers crossed it's going to be a mild respiratory virus season this year.
00:33:13: That's all for today.
00:33:14: As always if you have any comments questions suggestions please feel free to write an email to virallogicalatpodcastworkstation.com.
00:33:23: And if you like the podcast, feel free to support us on Steady.
00:33:26: Thanks for listening and until next week!
00:34:06: Bye.
New comment